RYVU
Ryvu is a biopharmaceutical company developing small molecule therapies that address clinical limitations of current treatments in oncology.
RYVU
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2007-01-01
Address:
Krakow, Malopolskie, Poland
Country:
Poland
Website Url:
http://www.ryvu.com
Total Employee:
101+
Status:
Active
Contact:
48 12 297 46 90
Email Addresses:
[email protected]
Total Funding:
27.99 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics Wordpress Plugins
Similar Organizations
Celator Pharmaceuticals
Celator Pharmaceuticals is a biopharmaceutical company developing therapies to treat cancer, using the drug ratio technology platform.
Vero Biotech
Vero Biotech is a biopharmaceutical company that commercializes inhaled nitric oxide delivery systems for healthcare providers.
Immutep
Immutep is a biopharmaceutical company developing immunotherapeutics in oncology.
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
Current Employees Featured
Founder
Stock Details
Investors List
European Investment Bank
European Investment Bank investment in Venture Round - Ryvu
National Center for Research & Development
National Center for Research & Development investment in Grant - Ryvu
Key Employee Changes
| Date | New article |
|---|---|
| 2022-01-17 | Ryvu Therapeutics appoints Hendrik Nogai, M.D. as Chief Medical Officer |
Official Site Inspections
http://www.ryvu.com Semrush global rank: 3.47 M Semrush visits lastest month: 4.36 K
- Host name: 104.21.2.242
- IP address: 104.21.2.242
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Ryvu"
RYVU
RYVU is an international collaborative research project looking at how volunteering affects skills, employability, and inequalities experienced by young refugees in Uganda.See details»
About — RYVU
RYVU is an international collaborative research project aiming to: Develop new understandings of volunteering that reflect the experiences of refugees in Uganda. Build knowledge on the relationships between volunteering and the …See details»
Home - Ryvu Therapeutics
Ryvu Therapeutics is a clinical stage biopharmaceutical company developing novel small molecule therapies addressing high value emerging targets in precision oncology.See details»
Ryvu Corporate Presentation
Multi-target research collaboration: Ryvu is conducting discovery and research activities to develop multiple small molecule programs targeting immune modulation in cancer and …See details»
Blog — RYVU
Dec 15, 2023 · The RYVU project is celebrating this International Volunteer Day with the launch of a series of policy briefings and interactive games in Arabic, English, French and Swahili, …See details»
Ryvu Corporate Presentation
Ryvu at a glance 1 As of 21 September 2022 Listed on the Warsaw Stock Exchange • One of the largest biotech companies in the region, headquartered in Krakow, Poland • $9.7m cash …See details»
Ryvu Therapeutics - LinkedIn
Ryvu Therapeutics | 10,593 followers on LinkedIn. Developing novel treatments at the forefront of oncology | Ryvu Therapeutics is a clinical-stage drug discovery and development company …See details»
Ryvu - Crunchbase Company Profile & Funding
Ryvu is a biopharmaceutical company developing small molecule therapies that address clinical limitations of current treatments in oncology. View contacts for Ryvu to access new leads and …See details»
Expansion of Clinical Development of RVU120 in Low-Risk …
KRAKOW, Poland, Oct. 20, 2023 /PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies …See details»
nCage Therapeutics and Ryvu Have Agreed to a Research …
Oct 29, 2024 · nCage Therapeutics and Ryvu have agreed to a Research collaboration to develop a next-generation antibody-drug conjugate (ADC) platform. nCage has developed a TRAP …See details»
RYVU (EGFF) - European Investment Bank
Aug 16, 2022 · The purpose of the loan is to provide direct equity-type financing under the European Growth Finance Facility ("EGFF"), a product under EFSI guarantee, to finance …See details»
Ryvu Corporate Presentation - Ryvu Therapeutics
Ryvu at a glance 1 As of 10 March 2022 Listed on the Warsaw Stock Exchange • One of the largest biotech companies in the region, headquartered in Krakow, Poland • ~$15.7m cash …See details»
Ryvu Therapeutics First Quarter 2024 Financial Results and …
KRAKOW, Poland, May 15, 2024 /PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies …See details»
Ryvu Therapeutics Summarizes 2023 Fiscal Year and Provides …
KRAKOW, Poland, March 13, 2024 /PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small-molecule therapies …See details»
Ryvu Therapeutics Reports 2024 Half-Year Financial Results and …
KRAKOW, Poland, Sept. 12, 2024 /PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies …See details»
Abstract - American Association for Cancer Research
Jul 1, 2021 · Ryvu has developed a new generation of potent, direct and selective small-molecule STING agonists. The compounds are characterized by drug-like properties and high in vitro …See details»
Corporate Information - Ryvu Therapeutics
The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send …See details»
Ryvu Corporate Presentation September 2021 - Ryvu Therapeutics
Ryvu at a glance • Wholly owned, first-in-class, selective, oral CDK8/19 inhibitor • Phase Ib study in AML/MDS: Early signs of efficacy reported at EHA 2021; further enrollment ongoing • Phase …See details»
Ryvu Therapeutics presents clinical and preclinical data on RVU120 ...
Oct 23, 2024 · Ryvu Therapeutics is a clinical-stage drug discovery and development company focused on novel small-molecule therapies that address emerging targets in oncology.See details»
Nivolumab in Patients With Advanced or Metastatic Malignancies ...
1 day ago · PURPOSETo report on CheckMate 627 (ClinicalTrials.gov identifier: NCT02832167), a phase II adaptive basket design trial of nivolumab in uncommon advanced/metastatic …See details»